These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 32179412

  • 21. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
    Tadmor T, Bejar J, Attias D, Mischenko E, Sabo E, Neufeld G, Vadasz Z.
    Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
    [Abstract] [Full Text] [Related]

  • 22. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
    Wang J, Ishii T, Zhang W, Sozer S, Dai Y, Mascarenhas J, Najfeld V, Zhao ZJ, Hoffman R, Wisch N, Xu M.
    Leukemia; 2009 Sep; 23(9):1577-86. PubMed ID: 19387466
    [Abstract] [Full Text] [Related]

  • 23. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.
    Pozdnyakova O, Wu K, Patki A, Rodig SJ, Thiele J, Hasserjian RP.
    Mod Pathol; 2014 Nov; 27(11):1447-54. PubMed ID: 24762543
    [Abstract] [Full Text] [Related]

  • 24. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
    Mahjoub S, Baccouche H, Sahnoun M, Kaabi H, Manai Z, Slama H, Ben Romdhane N.
    Tunis Med; 2015 Jul; 93(7):474-7. PubMed ID: 26757507
    [Abstract] [Full Text] [Related]

  • 25. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G.
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
    [Abstract] [Full Text] [Related]

  • 26. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
    Yang N, Park S, Cho MS, Lee M, Hong KS, Mun YC, Seong CM, Huh HJ, Huh J.
    Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
    [Abstract] [Full Text] [Related]

  • 27. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
    Toyama K, Karasawa M, Yokohama A, Mitsui T, Uchiumi H, Saitoh T, Handa H, Murakami H, Nojima Y, Tsukamoto N.
    Intern Med; 2011 Jul; 50(21):2557-61. PubMed ID: 22041356
    [Abstract] [Full Text] [Related]

  • 28. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
    Macedo LC, de Cesare Quintero F, Pagliari-E-Silva S, Pagnano KB, Rodrigues C, de Alencar JB, Sell AM, Visentainer JE.
    Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
    [Abstract] [Full Text] [Related]

  • 29. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B, Diral E, Donsante S, Di Marzo N, Mottadelli F, Cardinale L, Dander E, Isimbaldi G, Pioltelli P, Biondi A, Riminucci M, D'Amico G, Elli EM, Pievani A, Serafini M.
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [Abstract] [Full Text] [Related]

  • 30. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C, Huh HJ, Mun YC, Seong CM, Chung WS, Huh J.
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [Abstract] [Full Text] [Related]

  • 31. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 32. Canonical Wnt/β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis.
    Lucijanic M, Livun A, Tomasovic-Loncaric C, Stoos-Veic T, Pejsa V, Jaksic O, Prka Z, Kusec R.
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):523-526. PubMed ID: 27381374
    [Abstract] [Full Text] [Related]

  • 33. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E, Passamonti F, Rumi E, Pietra D, Elena C, Arcaini L, Pascutto C, Castello A, Cazzola M, Magrini U, Lazzarino M.
    Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
    [Abstract] [Full Text] [Related]

  • 34. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA, Smith-Gagen JA.
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [Abstract] [Full Text] [Related]

  • 35. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 36. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
    O'Sullivan J, Mead AJ.
    Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537
    [Abstract] [Full Text] [Related]

  • 37. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA.
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [Abstract] [Full Text] [Related]

  • 38. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
    Borovecki A, Skrtić A, Paro MM, Lasan R, Dominis M.
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
    [Abstract] [Full Text] [Related]

  • 39. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 40. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H, Shih LY, Michelson AD, Dunn P, Frelinger AL, Wang PN, Kuo MC, Lin TL, Wu JH, Tang TC.
    Acta Haematol; 2013 Apr; 130(3):181-7. PubMed ID: 23751441
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.